Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061906 · ClinicalTrials.gov registry record · Phase 2

Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
2
Study locations

NCT00061906: Completed Phase 2 study of Head and Neck Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

NCT00061906 is a Phase 2 study of Head and Neck Cancer that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 25 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061906, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG celecoxib

Study Locations (2)

Ohio

  • Ohio State University Comrehensive Cancer Center - Columbus

Texas

  • University of Texas - MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2003-01
Est. Completion 2006-06
Phase Phase 2
Ohio State University Comprehensive Cancer Center

341 total trials

What the finished NCT00061906 record still lists

NCT00061906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which celecoxib is the first listed.

NCT00061906 reports a single indexed study location in Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT00061906 about?

NCT00061906 is a clinical study titled "Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer". RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid can...

What is the current status of trial NCT00061906?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-01. Estimated completion is 2006-06.

What conditions does trial NCT00061906 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00061906?

The interventions under investigation include: celecoxib (DRUG).

Who is sponsoring clinical trial NCT00061906?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00061906 being conducted?

This trial has 2 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00061906's enrollment target sits among peer trials

25 196th of 250 higher than 47 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00061906, the US trial registry maintained by the National Library of Medicine. NCT00061906 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.